Patrick Campbell

Two studies examining RCTs of herbal and dietary supplements found none of these supplements provided a clinically meaningful reduction in body weight among patients with overweight or obesity.

An analysis presented ahead of ACC.21 details the increased risk of MACE associated with prediabetes, suggesting patients were at nearly twice the risk of experiencing a major cardiovascular event.

A systematic review and meta-analysis of studies examining pediatric type 2 diabetes indicate hypertension or albuminuria was present among approximately 20% of children with type 2 diabetes.

An analysis from ACC.21 is providing an overview of the impact of prediabetes compared to normoglycemia on risk for major adverse cardiovascular disease events.

Data from an analysis of NHANES suggest nearly 1-in-5 adults with hypertension were also taking medication that may increase blood pressure.

An analysis of claims data from more than 7k patients suggests patients with severe obesity and type 2 diabetes who underwent bariatric surgery experienced a 68% reduction in cardiac mortality and 34% reduction in cardiac events compared against standard medical management.

The AHA has released a scientific statement aimed at outlining the current knowledge base related to risk of cardiovascular disease associated with hormonal therapies used in the treatment of breast and prostate cancer.

New data from an analysis of the ISCHEMIA trial is providing insight into the days alive out of hospital with an initial invasive or conservative approach to the management of stable ischemic heart disease.

Data from more than 1500 general practices are providing a comprehensive overview of the impact of obesity on risk of severe COVID-19 outcomes in England—suggesting each BMI increase beyond 23 kg/m2 increased risk of hospital admission and death.

New information from a phase 3 trial used as part of the FDA approval is providing insight into the safety and efficacy of dasiglucagon for treatment of severe hypoglycemia in adult patients with type 1 diabetes.

The USPSTF recommendation reaffirms their 2015 stance, which calls for screening adults 18 years or older with office blood pressure measurement and obtaining measurements outside of a clinical setting for diagnostic confirmation before starting treatment.

Results of 1-year follow-up from the Harmony TPV Clinical trial provide insight into the safety and efficacy of the recently approved Harmony TPV system in patients with congenital heart disease and severe pulmonary regurgitation.

The US FDA announced dapagliflozin (Farxiga) received approval for reducing the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression in a statement on April 30.

A study from McMaster University is providing updated information related to the prevalence of hypertension and albuminuria in younger patients with type 2 diabetes.

An analysis of data from NYU Langone provides perspective into the rapid decline of emergency department presentations for acute myocardial infarction that occurred during the peak of the COVID-19 pandemic.

A systematic review and meta-analysis of data from nearly 2 dozen studies is providing new insight into the phenotypes of patients with diabetes associated with worse outcomes from COVID-19.

An analysis comparing a national registry against ISCHEMIA enrollment criteria suggests trial eligibility represents less than 2% of all patients undergoing PCI and less than a third of patients undergoing PCI with stable ischemic heart disease.

An SCAI 2021 analysis of more than 4k patients with characteristics similar to those included in the TWILIGHT trial indicates extended-duration DAPT, defined as a duration of more than 12 months post-PCI, was a more efficacious approach than short-term DAPT in this patient population.

An analysis of data from the Australian InFANT program suggests early lifestyle patterns or parental influences can help to predict obesity or BMI trajectory in early life.

A new analysis of claims data performed by clinicians at Penn Medicine suggests less than 1% of patients with ASCVD initiated therapy with a PCKS9 inhibitor from 2015-2019.

The USPSTF has released a recommendation statement related to hypertension screenings among adults without known hypertension.

A retrospective analysis of matched cohorts has led investigators to suggest bariatric surgery should be viewed as a first-line treatment for the management of obesity in patients with type 2 diabetes.

An analysis of the National Inpatient Sample presented at the European Heart Rhythm Association 2021 Congress is shedding light on cannabis use and the risk of death among patients with arrhythmia.

An analysis of dietary patterns from more than 4000 men in NHANES suggests a diet with a greater intake of inflammatory foods was associated with a nearly 30% increase in odds of developing testosterone deficiency.

Data from a cohort of more than 50k French women indicates the presence of migraine prior to entering menopause was associated with a nearly 30% greater risk of developing hypertension.

Dr. Gregory Weiss, a cardiovascular anesthesiologist, breaks down and provides real-world perspective on the application of a recent scientific statement from the AHA and ASA on perioperative management to lower stroke risk in patients undergoing noncardiac and nonneurological procedures.

An analysis of more than 400 women with peripartum cardiomyopathy is providing insight into a group of genetic variants that could help identify patients who are genetically predisposed to the rare cardiovascular condition.

Data from phone interviews indicate patients who had cardiovascular surgeries delayed or cancelled as a result of the COVID-19 pandemic may have experienced additional psychological stress as a result.

Data from a pair of Washington, DC-based medical centers are providing an overview of the impact gender-affirming hormone therapy can have on blood pressure in transgender individuals.

The largest study of its kind is providing insight related to changes in blood pressure seen among transgender patients initiating gender-affirming hormone therapy.